| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
,
*
Dipartimento di Biologia, Università di Trieste, Trieste, Italy;
Istituto di Ricovero e Cura a Carattere Sperimentale, Burlo Garofolo, Trieste, Italy;
Biosciences Division, Los Alamos National Laboratory, Los Alamos, NM 87545; and
Scuola Internazionale Superiore di Studi Avanzati, Trieste, Italy
Celiac disease (CD) is an intestinal malabsorption characterized by intolerance to cereal proteins accompanied by immunological responses to dietary gliadins and tissue transglutaminase, an autoantigen located in the endomysium. Tissue transglutaminase belongs to the family of enzymes that catalyze protein cross-linking reactions and is constitutively expressed in many tissues as well as being activated during apoptosis. The role of gliadins in eliciting the immune response in CD and how transglutaminase is linked to the primary reaction are still unclear. In this work, we report the production and analysis of six phage Ab libraries from the peripheral and intestinal lymphocytes of three CD patients. We were able to isolate Abs to transglutaminase from all intestinal lymphocytes libraries but not from those obtained from peripheral lymphocytes. This is in contrast to Abs against gliadin, which could be obtained from all libraries, indicating that the humoral response against transglutaminase occurs at the local level, whereas that against gliadin occurs both peripherally and centrally. Abs from all three patients recognized the same transglutaminase epitopes with a bias toward the use of the VH5 Ab variable region family. The possible role of these anti-transglutaminase Abs in the onset of CD and associated autoimmune pathologies is discussed.
This article has been cited by other articles:
|
|
 |
|
  M. Maglio, F. Florian, M. Vecchiet, R. Auricchio, F. Paparo, R. Spadaro, D. Zanzi, L. Rapacciuolo, A. Franzese, D. Sblattero, et al. Majority of Children With Type 1 Diabetes Produce and Deposit Anti-Tissue Transglutaminase Antibodies in the Small Intestine Diabetes, July 1, 2009; 58(7): 1578 - 1584. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kaukinen, P. Collin, and M. Maki Latent coeliac disease or coeliac disease beyond villous atrophy? Gut, October 1, 2007; 56(10): 1339 - 1340. [Full Text] [PDF]
|
|
|
|
|
|
G. Byrne, F. Ryan, J. Jackson, C. Feighery, and J. Kelly Mutagenesis of the catalytic triad of tissue transglutaminase abrogates coeliac disease serum IgA autoantibody binding Gut, March 1, 2007; 56(3): 336 - 341. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T T Salmi, P Collin, I R Korponay-Szabo, K Laurila, J Partanen, H Huhtala, R Kiraly, L Lorand, T Reunala, M Maki, et al. Endomysial antibody-negative coeliac disease: clinical characteristics and intestinal autoantibody deposits Gut, December 1, 2006; 55(12): 1746 - 1753. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D Sblattero, A Ventura, A Tommasini, L Cattin, S Martelossi, F Florian, R Marzari, A Bradbury, and T Not Cryptic gluten intolerance in type 1 diabetes: identifying suitable candidates for a gluten free diet Gut, January 1, 2006; 55(1): 133 - 134. [Full Text] [PDF]
|
|
|
|
 |
|
 F. Fischetti, P. Durigutto, V. Pellis, A. Debeus, P. Macor, R. Bulla, F. Bossi, F. Ziller, D. Sblattero, P. Meroni, et al. Thrombus formation induced by antibodies to {beta}2-glycoprotein I is complement dependent and requires a priming factor Blood, October 1, 2005; 106(7): 2340 - 2346. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Sblattero, F. Maurano, G. Mazzarella, M. Rossi, S. Auricchio, F. Florian, F. Ziberna, A. Tommasini, T. Not, A. Ventura, et al. Characterization of the Anti-Tissue Transglutaminase Antibody Response in Nonobese Diabetic Mice J. Immunol., May 1, 2005; 174(9): 5830 - 5836. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I R Korponay-Szabo, T Halttunen, Z Szalai, K Laurila, R Kiraly, J B Kovacs, L Fesus, and M Maki In vivo targeting of intestinal and extraintestinal transglutaminase 2 by coeliac autoantibodies Gut, May 1, 2004; 53(5): 641 - 648. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Baldas, A. Tommasini, D. Santon, T. Not, T. Gerarduzzi, G. Clarich, D. Sblattero, R. Marzari, F. Florian, S. Martellossi, et al. Testing for Anti-Human Transglutaminase Antibodies in Saliva Is Not Useful for Diagnosis of Celiac Disease Clin. Chem., January 1, 2004; 50(1): 216 - 219. [Full Text] [PDF]
|
|
|
|
 |
|
 S Davison Coeliac disease and liver dysfunction Arch. Dis. Child., October 1, 2002; 87(4): 293 - 296. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Collin, K. Kaukinen, M. Valimaki, and J. Salmi Endocrinological Disorders and Celiac Disease Endocr. Rev., August 1, 2002; 23(4): 464 - 483. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C Esposito, F Paparo, I Caputo, M Rossi, M Maglio, D Sblattero, T Not, R Porta, S Auricchio, R Marzari, et al. Anti-tissue transglutaminase antibodies from coeliac patients inhibit transglutaminase activity both in vitro and in situ Gut, August 1, 2002; 51(2): 177 - 181. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
